Concepedia

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R.S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, S. Qin, M. Ikeda, R. Xu, Julien Edeline, B-Y. Ryoo, Z. Ren,

Annals of Oncology · 2022 · 192 citations · 0 references

DOI

Concepts